Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study)

赛马鲁肽 杜拉鲁肽 医学 内科学 胃肠病学 2型糖尿病 内分泌学 糖尿病 艾塞那肽 利拉鲁肽
作者
Tomohiko Kimura,Yukino Katakura,Masashi Shimoda,Fumiko Kawasaki,Mizuho Yamabe,Fuminori Tatsumi,Michihiro Matsuki,Yuichiro Iwamoto,Takatoshi Anno,Yoshiro Fushimi,Shinji Kamei,Yukiko Kimura,Shuhei Nakanishi,Tomoatsu Mune,Kohei Kaku,Hideaki Kaneto,COMING study Group
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (12): 3632-3647 被引量:22
标识
DOI:10.1111/dom.15258
摘要

AIM: To compare the clinical usefulness of once-weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide at the doses approved for use in Japanese patients with type 2 diabetes. METHODS: In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial. The primary endpoint was the difference of HbA1c level between the two groups at 24 weeks. RESULTS: HbA1c level at 24 weeks was significantly lower in the semaglutide group (7.9 ± 0.5%-6.7 ± 0.5%) compared with the dulaglutide group (8.1 ± 0.6%-7.4 ± 0.8%) (p < .0001). Reduction in body mass index and visceral fat area were also more significant in the semaglutide group (p < .05, respectively). The achievement rate of HbA1c <7% was higher in the semaglutide group (p < .0001). The parameters such as low-density lipoprotein cholesterol, alanine aminotransferase and γ-glutamyl transpeptidase were decreased in the semaglutide group. Surprisingly, only semaglutide group significantly improved the apolipoprotein B/A1 ratio, which is considered a useful myocardial infarction risk index. Using computed tomography, the liver to spleen ratio was significantly elevated only in the semaglutide group. In contrast, gastrointestinal symptoms were observed in 13.2% of dulaglutide and 46.3% of semaglutide group (p < .01). The Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms were also superior in the dulaglutide group. CONCLUSIONS: This prospective trial showed that semaglutide has more pronounced glucose- and body mass index-lowering effects and reduces liver fat percentage and visceral fat area and that dulaglutide has less gastrointestinal symptoms and superior Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被辣辣医生采纳,获得10
刚刚
刚刚
1秒前
西西公主完成签到,获得积分10
1秒前
gyq发布了新的文献求助10
1秒前
haining的应助被stc采纳,获得10
1秒前
Momo发布了新的文献求助10
1秒前
TinkerBell发布了新的文献求助10
2秒前
草莓苹果发布了新的文献求助10
2秒前
周小鱼发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
小茉莉发布了新的文献求助10
2秒前
香蕉觅云的应助被amour采纳,获得10
2秒前
sunny的应助被ST采纳,获得10
2秒前
诚心的以寒完成签到,获得积分10
2秒前
2秒前
3秒前
zhutu完成签到,获得积分10
3秒前
彭于晏的应助被cz采纳,获得30
3秒前
OK发布了新的文献求助10
4秒前
我是老大的应助被aotuxiaodi采纳,获得10
4秒前
科研通AI6.2的应助被健忘身影采纳,获得10
4秒前
陆小果完成签到,获得积分10
4秒前
酷波er的应助被可爱觅松采纳,获得10
4秒前
热情的如雪完成签到 ,获得积分10
4秒前
yhy发布了新的文献求助10
5秒前
cwy完成签到,获得积分20
5秒前
5秒前
5秒前
5秒前
6秒前
秋风的应助被代渺采纳,获得10
6秒前
FDSDFSDF完成签到,获得积分10
6秒前
南下1212发布了新的文献求助10
6秒前
6秒前
7秒前
小星星完成签到,获得积分10
7秒前
调皮彤完成签到 ,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949